PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Dec. 17, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 13, 2024, the company approved non-statutory stock options to purchase an aggregate of 1,725 shares of its common stock and 5,060 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to eight new employees. The awards were made pursuant to the Nasdaq inducement grant exception as a component of the new hires' employment compensation.
新澤西州禾倫，2024年12月17日 /PRNewswire/ -- PTC Therapeutics, Inc. (納斯達克: PTCT) 今天宣佈，2024年12月13日，公司批准向八名新員工授予非法定股票期權，以購買總計1,725股普通股和5,060個限制性股票單位（"RSUs"），每個單位代表在歸屬後有權獲得一股普通股。這些獎勵是根據納斯達克誘導授予例外，作爲新員工就業薪酬的一部分。
The inducement grants were approved by PTC's Compensation Committee on Dec. 13, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
這些誘導授予於2024年12月13日由PTC的薪酬委員會批准，並作爲吸引每位員工接受公司工作的誘導材料，根據納斯達克上市規則5635(c)(4)進行。
All stock option awards have an exercise price of $46.37 per share, the closing price of PTC's common stock on Dec. 13, 2024, the date of the grant. The stock options each have a 10-year term and vest over four years, with 25% of the original number of shares vesting on the first anniversary of the applicable employee's new hire date and 6.25% of the original number of shares vesting at the end of each subsequent three-month period thereafter until fully vested, subject to the employee's continued service with the company through the applicable vesting dates. The RSUs each will vest over four years with 25% of the original number of shares vesting on each annual anniversary of the applicable employee's new hire date until fully vested, subject to the employee's continued service with the company through the applicable vesting dates.
所有股票期權獎勵的行使價格爲每股46.37美元，爲PTC普通股在2024年12月13日授予日期的收盤價格。每個股票期權的有效期爲10年，並在四年內歸屬，其中25%的原始股份在相關員工的新僱傭日期的第一週年時歸屬，之後每個三個月週期結束時有6.25%的原始股份歸屬，直到完全歸屬，前提是員工在相關歸屬日期繼續爲公司服務。每個RSU將在四年內歸屬，25%的原始股份在相關員工的新僱傭日期的每年週年時歸屬，直到完全歸屬，前提是員工在相關歸屬日期繼續爲公司服務。
ABOUT PTC THERAPEUTICS, INC.
PTC is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to children and adults living with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at and follow us on Facebook, Instagram, LinkedIn and X.
關於PTC THERAPEUTICS, INC.
PTC是一家全球生物製藥公司，專注於發現、開發和商業化臨床差異化的藥物，爲患有罕見疾病的兒童和成人提供益處。PTC的創新能力體現在識別新療法和全球商業化產品的基礎上，這推動了對強大而多樣化的變革性藥物管道的投資。PTC的使命是爲幾乎沒有治療選擇的患者提供最佳治療的獲取途徑。PTC的策略是利用其強大的科學和臨床專業知識以及全球商業基礎設施，將療法帶給患者。PTC認爲這使它能夠爲所有利益相關者最大化價值。要了解更多關於PTC的信息，請訪問我們並在Facebook、Instagram、LinkedIn和X上關注我們。
For more information please contact:
欲了解更多信息，請聯繫人：
Investors:
Ellen Cavaleri
+1 (615) 618-8228
[email protected]
投資者：
艾倫·卡瓦萊裏
+1 (615) 618-8228
[email protected]
Media:
Jeanine Clemente
+1 (908) 912-9406
[email protected]
媒體：
珍妮娜·克萊門特
+1 (908) 912-9406
[email protected]
SOURCE PTC Therapeutics, Inc.
來源 PTC Therapeutics, Inc.
